MYPHALOR Trademark
Trademark Overview
On Thursday, June 2, 2022, a trademark application was filed for MYPHALOR with the United States Patent and Trademark Office. The USPTO has given the MYPHALOR trademark a serial number of 97441094. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Tuesday, November 19, 2024. This trademark is owned by TEVA PHARMACEUTICALS USA, Inc.. The MYPHALOR trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
General Information
| Serial Number | 97441094 |
| Word Mark | MYPHALOR |
| Filing Date | Thursday, June 2, 2022 |
| Status | 732 - THIRD EXTENSION - GRANTED |
| Status Date | Tuesday, November 19, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, April 4, 2023 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations, namely, oral and injectable contraceptives, women's hormone replacement medications |
| Pseudo Mark | MY PHALOR |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, June 13, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | TEVA PHARMACEUTICALS USA, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Parsippany, NJ 07054 |
| Party Name | TEVA PHARMACEUTICALS USA, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Parsippany, NJ 07054 |
Trademark Events
| Event Date | Event Description |
| Tuesday, February 28, 2023 | ASSIGNED TO EXAMINER |
| Monday, June 6, 2022 | NEW APPLICATION ENTERED |
| Monday, June 13, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, March 2, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, March 15, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, April 4, 2023 | PUBLISHED FOR OPPOSITION |
| Tuesday, April 4, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, May 30, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, November 21, 2023 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, November 21, 2023 | SOU EXTENSION 1 FILED |
| Tuesday, November 21, 2023 | SOU EXTENSION 1 GRANTED |
| Thursday, November 23, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, May 6, 2024 | SOU EXTENSION 2 FILED |
| Monday, May 6, 2024 | SOU EXTENSION 2 GRANTED |
| Tuesday, May 7, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, November 19, 2024 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, November 19, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, November 19, 2024 | SOU EXTENSION 3 FILED |
| Tuesday, November 19, 2024 | SOU EXTENSION 3 GRANTED |
| Monday, May 6, 2024 | SOU TEAS EXTENSION RECEIVED |
